TY  - JOUR
T1  - CLinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction
AU  - Horowitz RS, Dart RC, Gomez HF
Y1  - 1996/02/26
N1  - 10.1001/archinte.1996.00440040134015
JO  - Archives of Internal Medicine
SP  - 456
EP  - 458
VL  - 156
IS  - 4
N2  - The macrolide class of antibiotics, including erythromycin and troleandomycin, is associated with clinically significant adverse drug interactions. This results from macrolide inhibition of cytochrome P-450 metabolism of numerous xenobiotics, resulting in elevated serum drug levels and clinical intoxication. Animal studies, however, suggest that clarithromycin, the newest approved macrolide antibiotic, has less potential for adverse drug reactions. We describe a patient who, on her fifth day of clarithromycin therapy, developed clinical ergotism (ie, hypertension, lingual ischemia, and peripheral cyanosis) several hours after administration of her usual 2-mg dose of ergotamine tartrate. To our knowledge, this is the first report of clinical ergotism precipitated by clarithromycin-ergotamine interaction and suggests that, like other macrolide antibiotics, ergot preparations should be avoided in patients who are taking clarithromycin.(Arch Intern Med. 1996;156:456-458)
SN  - 0003-9926
M3  - doi: 10.1001/archinte.1996.00440040134015
UR  - http://dx.doi.org/10.1001/archinte.1996.00440040134015
ER  -